Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Date:6/12/2013

develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of June 12,
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
2. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
3. Amgen And Astellas Announce Japan Alliance
4. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
8. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
9. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
10. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
11. Amgen Announces Webcast of 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... a $15 million milestone payment from GSK related to advancing ... with familial amyloid polyneuropathy (FAP).  "We are ... Rx , and plan to report data from the Phase ... the fifteen months of dosing and are now receiving ISIS-TTR ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... Inc. (Nasdaq: STXS ) announced today that the underwriters ... have exercised in full their over-allotment option to purchase an ... 7,475,000 shares of Stereotaxis common stock in the offering, including ... sold at a price to the public of $4.00 per ...
... 12 Leaders of the medical technology industry ... E. Washington Convention Center for the third annual ... mix of medical technology executives, innovators, policymakers, media, ... and 32 states, are expected to attend this ...
Cached Medicine Technology:Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 2Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 3Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 2Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 3
(Date:3/2/2015)... 2015 Representatives with BNatrl ( ... launched a multivitamin supplement that’s specifically designed for ... for BNatrl, said the multivitamin, which launched Jan. ... other world-class athletes. , "Being an avid marathon ... whole food multivitamin to improve my performance,” said ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... Final Cut Pro X plugin specialists have ... Film Studios. , “The TranStatic Volume 2 plugin gives users ... CEO of Pixel Film Studios. “TranStatic Volume 2 is a ... editors toolbox.” , With TranStatic Volume 2 users can transition ... scrambling effects from Pixel Film Studios. Users have total control ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
Breaking Medicine News(10 mins):Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... of brain tumor , , MONDAY, June 2 (HealthDay News) -- ... malignant brain tumor that was diagnosed last month. , The ... an especially lethal type of brain tumor, at Duke University ... Massachusetts Democrat,s office said he would be operated on by ...
... in 81 years the International Congress of Genetics takes place ... Nobel Prize winners get together with more than 2000 scientists ... genome analysis. The congress, which takes place for the 20th ... also being Berlin. Congress Chairman is Prof. Rudi Balling, Scientific ...
... PETERSBURG, Fla., June 2 The Advanced,Wound Management Division ... that its negative pressure wound therapy (NPWT) products will ... included in the,first phase of the competitive bidding program ... in the U.S. The program, which is,scheduled to take ...
... completed ... phase I studies, SAN ... of a worldwide exclusive agreement entered into in Feb,2008, GlaxoSmithKline (GSK) ... original agreement, GSK has rights to develop,manufacture and commercialize FLAP (5-Lipoxygenase ...
... Imagine being able to communicate,your practice,s message to ... practice growth and development. That is the focus of ... parent company of JG Pads, a pharmaceutical sales,support company ... United States since 1993. Because of its success, MarketHATCH ...
... Scientists at the University of Liverpool have found that ... antibiotics, suggesting that the infection is unlike the bacteria ... resistant to antibiotics and can sometimes go undetected in ... spread to humans. The team tested the strains found ...
Cached Medicine News:Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 2Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 3Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 4Health News:6 Nobel Prize Winners at International Congress of Genetics 2Health News:6 Nobel Prize Winners at International Congress of Genetics 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline 2Health News:Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 2Health News:Salmonella in garden birds responsive to antibiotics 2
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
... used to seal the arterial puncture site. Duett ... the arteriotomy and the tissue tract with a ... a balloon catheter and procoagulant - the Duett ... stop the bleeding. The Duett is unique in ...
Medicine Products: